Caris Life Sciences® (Caris) is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets.
External link for Caris Life Sciences
750 W John Carpenter Fwy
Irving, Texas 75039, US
4610 S 44th Pl
Phoenix, Arizona 85040, US
St. Jakobsstrasse
199, 4052 Basel, CH
Register Today! ✅ Join Caris Life Sciences and Dr. Jai Patel, PharmD, as we explore the clinical impact of DPYD testing, the evidence from ongoing trials, and the advocacy driving change across oncology. Gain insight into why precision dosing is becoming a new frontier in personalized medicine. Don't miss this discussion: https://lnkd.in/gpaxNSFq
This content isn’t available here
Access this content and more in the LinkedIn app
Caris and collaborators within the Caris Precision Oncology Alliance (Caris POA) will collectively present 19 studies across a range of breast cancer types at the San Antonio Breast Cancer Symposium (SABCS) from December 9-12, 2025. “SABCS is the premier global stage for advancing breast cancer research, and we are excited to share how Caris’ multiomic tumor profiling is helping define molecularly distinct patient groups,” said George Sledge, Jr., MD, Caris EVP and Chief Medical Officer. Learn more: https://lnkd.in/gyff6BN4
Join Caris Life Sciences at ASH 2025 in Orlando. We're excited to connect with oncology leaders and share how our precision medicine innovations are advancing cancer care. Visit us at Booth 281. Learn more: https://lnkd.in/dxUN6zBk #ASH25
Caris Life Sciences is pleased to announce that the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute has joined the Caris Precision Oncology Alliance™ (Caris POA). “It is great to welcome UAMS to the Caris POA. Their unwavering commitment to excellence perfectly aligns with our commitment to advance biomarker-driven precision oncology,” said James Hamrick, MD, MPH, Chairman of the Caris POA. Learn more: https://lnkd.in/g3b-Xv42
Meet Maggie McCloskey, a lung cancer survivor and advocate for awareness. In 2021, Maggie received news that would change her life: stage IV lung cancer. But Maggie’s journey proves that cancer care today offers more hope than ever before. A friend recommended Caris Life Sciences for comprehensive molecular profiling. That advice led Maggie to turn fear into empowerment through genomic testing and Caris molecular profiling, a decision she calls pivotal: “Knowledge is power. Testing is power.” Maggie began mentoring newly diagnosed patients and became an active voice in the lung cancer community. Her goal is to ensure others understand the value of personalized medicine and the hope it brings. Learn more: https://ow.ly/E21X50XxSu9
Join Caris Life Sciences and Dr. Jai Patel, PharmD, as we explore the clinical impact of DPYD testing, the evidence from ongoing trials and the advocacy driving change across oncology. Gain insight into why precision dosing is becoming a new frontier in personalized medicine. Register now: https://ow.ly/uyj150Xx9yY
Caris announces the selection of 15 physician-scientists to participate in its 2025/2026 Caris Precision Oncology Alliance (Caris POA) Fellows Forum. This competitive two-year program provides early-career oncologists with hands-on training, mentorship and access to real-world molecular data, empowering them to develop and test clinically meaningful precision medicine hypotheses. “Investing in the next generation of oncology leaders allows us to advance research while also accelerating discoveries that will change how we diagnose and treat cancer,” said James Hamrick, MD, MPH Chairman of the Caris Precision Oncology Alliance. “This year’s class represents the future of precision oncology and we’re excited to support their journey.” Learn more: https://ow.ly/6W2f50Xvare #precisionmedicine
In recognition of Lung Cancer Awareness Month, we highlight a recent study in JAMA Oncology that found RET fusion-positive NSCLC tumors express membrane targets that could provide potential avenues for novel therapies. The study used Caris’ whole transcriptome sequencing data from >19,700 lung cancer patients to confirm target expression. https://ow.ly/fAk950XrWUp #LungCancerAwareness
Caris Life Sciences reposted this
In this episode of OncoTalks, Ontada's Paul Conkling, MD, and Caris Life Sciences' David Spetzler, MS, PhD, MBA, explore how comprehensive molecular profiling and AI are shaping the future of cancer care: 🌟 The advantages of broad molecular profiling over smaller panels, including its superior accuracy in detecting critical biomarkers and identifying eligibility for emerging therapies 🌟 How AI is transforming treatment sequencing and improving patient outcomes 🌟 Key technical factors—such as microdissection and advanced extraction methods—that enhance the precision of both tissue and liquid biopsies 🌟 The importance of high assay coverage and the role of whole exome and transcriptome sequencing in delivering comprehensive diagnostic insights 🌟 The challenges of clinical validation and regulatory approval Listen now: https://lnkd.in/gdiZuPxB #AI #MolecularProfiling #Biomarkers #Oncology
Caris Life Sciences announced the company will attend upcoming Q4 investor conferences this year. Connect with Caris to schedule an investor meeting and learn more about our innovative solutions to transform healthcare. https://ow.ly/Kusc50XrZRr